To: Mr. Forthright who wrote (2380 ) 7/1/1998 10:29:00 PM From: chirodoc Read Replies (1) | Respond to of 5402
MORE PROOF ON THE SAFETY AND EFFICACY OF PFC'S Artificial blood works in test on baboons ...."There was absolutely no sign of any adverse reaction. We think this is a particularly important animal to deal since it is very similar to human response." By Raju Narisetti( Washington Times- March 20, 1994) A Yellow-Springs based scientist's pioneering work to develop synthetic blood is one step closer to reality. Synthetic Blood International Inc. said it successfully completed a test of artificial blood on baboons, the first step of a long testing process to get synthetic blood approved for human use. The bulk of the San Diego, Calif.-based company's research is conducted at the Kettering Labs in Yellow Springs by scientist Leland C. Clark Jr. Clark, who has more than 80 inventions to his credit, is best known for the 1952 heart-lung machine that allowed surgeons to perform heart surgery such as heart transplants, open heart and coronary by-pass operations. The baboon tests are critical to the startup company because Clark's approach- based on using fluorocarbons- departs from most other efforts that aim to artificially recreate hemoglobin, the red blood cell. Through most artificial blood products are not expected to be readily available for three to five years, demand for such blood is expected to be between $5 billion and $8 billion. Synthetic Blood also received a financial boost when New York's American Heritage Fund Inc., an investment company, acquired one million shares of common stock in a private placement. Terms were not disclosed. Synthetic stock, which is traded over the counter (symbol: SYBD), was last bid at 11/4. Since it was listed a year ago, the stock price has traded between a high of 31/2 and a low of 3/4 per share. American Heritage, which now owns 6.7 percent of Synthetic stock, manages a $150 million aggressive growth fund. Clark is the single largest shareholder in Synthetic with a 25 percent holding. The startup company has 20 million outstanding shares with a float - shares available for trading - of about four million shares. Both Clark and company officials cautioned that with another round of primate testing to follow and subsequent tests on humans, a synthetic blood product approved by the Food and Drug Administration is at least three years away. Clark, 75, came up with the idea of synthetic blood some 30 years ago but has since struggled to develop a liquid that can carry oxygen, which is the main function of blood. The baboon tests were conducted at the Southwest Biomedical Research Center in San Antonio, Texas, an independent testing facility that houses more than 3,000 primates. "The four baboons are still frolicking, a month and half later," said Robert J. Larsen, chief operating officer of Synthetic in a telephone interview from Rosarito, Mexico, just across the border from San Diego. Added Clark: "There was absolutely no sign of any adverse reaction. We think this is a particularly important animal to deal since it is very similar to human response."